Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
TGTX
Home
/
TGTX

NASDAQ
$61.63
$61.63

Overview

Price performance
Low
$60.33
High
$62.78
After hours. Last updated: Nov 4, 2026, 9:00 PM UTC
$
61.63
0.88 (1.45%)
Average, 50 days
$55.54
$44.10
Open
$62.00
Previous close
$60.75
52-week high
$63.60
Nov 2, 2026 (3 days ago)
52-week low
$26.76
Mar 12, 2026 (8 months ago)
130.31%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
9.43B
Volume
1 883 383
Total Return (3M)
26.45%
Total Return (1Y)
82.28%
11.61
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
Website
tgtherapeutics.com
Socials
About
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.

Frequently asked questions

TGTX · TG Therapeutics, Inc.

01What is TG Therapeutics, Inc. stock price today?

The current price of TGTX is $61.63 — it has increased by 1.45% since the previous close. Data as of Nov 4, 2026.

02Is TG Therapeutics, Inc. stock price growing?

TGTX is up 5.98% over the past week, up 13.52% over the past month and up 82.28% over the past year. The price is above its 200-day moving average of $44.10.

03What is TGTX stock forecast?

Analysts' average 12-month price target for TGTX is $80.50, which implies 30.62% upside from the current price. Individual estimates range from $78.00 to $83.00.

04What do analysts say about TGTX stock?

Of the 8 analysts covering TG Therapeutics, Inc., 1 rates it a strong buy, 6 rate it a buy and 1 rates it a strong sell. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

05What is TG Therapeutics, Inc. market cap?

TG Therapeutics, Inc. has a market capitalization of $9.43B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

06What were TG Therapeutics, Inc. earnings last quarter?

In its most recent quarterly report, TG Therapeutics, Inc. posted earnings of $0.05 per share against an estimate of $0.3057, missing expectations by 83.64%. Upcoming reports are listed in the earnings calendar.

07What is TG Therapeutics, Inc. revenue for the last quarter?

TG Therapeutics, Inc. reported revenue of $240.34M in its most recent quarter, which has increased by 70.27% compared with the same quarter a year earlier. Analysts had expected $229.77M.

08Who are TG Therapeutics, Inc. competitors?

Companies most comparable to TG Therapeutics, Inc. include Genmab A/S, Xencor, Inc., Celldex Therapeutics, Inc., Corvus Pharmaceuticals, Inc. and ADC Therapeutics S.A.

09How volatile is TGTX stock?

In the latest trading session TGTX moved between $60.33 and $62.78, a range of 3.98% of its current price.

10What are TGTX stock 52-week high and low?

Over the past 52 weeks TGTX has traded between $26.76 and $63.60. The current price is 3.10% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.